Please assess the completion status of the following clinical trial:

Trial Title: Therapy With an Oxytocin Adjunct for Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~• Current Major Depressive Episode~Exclusion Criteria~* Visual impairment~* Major medical illness \[A condition that is chronic and associated with impaired functioning, distress, or frequent medical intervention), in particular, subjects with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease~* Acute or chronic nasal diseases or obstruction~* Current (in the last month) use of any endocrine-relevant or psychotropic medication other than prescription antidepressants~* Current substance dependence or abuse~* Use of illicit drugs (stimulants, narcotics, psychedelics/hallucinogens, non-prescription medication) in the past 8 weeks~* Lifetime history of a psychosis (except if part of MDD) or pervasive developmental disorder~* Past or current comorbid axis-1 disorder except Dysthymia, Adjustment Disorder, Generalized Anxiety Disorder, Social Phobia, and Specific Phobia.~* Female Only: Females of child bearing potential cannot be pregnant or breastfeeding in order to participate in this study. They must not be planning to become pregnant, and must be willing to use appropriate contraception throughout the study.~* Female Only: To control for hormonal changes related to pregnancy, females will also be excluded if they have previously given birth.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Spray And Interpersonal Psychotherapy (Type: PLACEBO_COMPARATOR): Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
- Oxytocin Spray And Interpersonal Psychotherapy (Type: EXPERIMENTAL): Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.

Based on this trial design, predict the completion outcome and termination type (if applicable).